Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model

Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model

Abstract Multiple myeloma (MM) is a malignant plasma cell cancer. Mutations in RAS pathway genes are prevalent in advanced and proteasome inhibitor (PI) refractory MM. As such, we recently developed a VQ MM mouse model recapitulating human advanced/high-risk MM. Using VQ MM cell lines we conducted a...

Full description

Bibliographic Details
Main Authors: Evan Flietner, Zhi Wen, Adhithi Rajagopalan, Oisun Jung, Lyndsay Watkins, Joshua Wiesner, Xiaona You, Yun Zhou, Yuqian Sun, Brock Kingstad-Bakke, Natalie S. Callander, Alan Rapraeger, M. Suresh, Fotis Asimakopoulos, Jing Zhang
Format: Article
Language:English
Published: Nature Portfolio 2022-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-14114-z

Internet

https://doi.org/10.1038/s41598-022-14114-z

Similar Items